{"id":1011125,"date":"2026-10-18T18:13:10","date_gmt":"2026-10-18T22:13:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/"},"modified":"2026-10-18T18:13:10","modified_gmt":"2026-10-18T22:13:10","slug":"esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/","title":{"rendered":"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position:inside }\n.bwalignl { text-align: left }\n.bwlistdisc { list-style-type: disc }\n.bwlistdecimal { list-style-type: decimal }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology<\/b><\/p>\n<p class=\"bwalignc\"><i>Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations<\/i><\/p>\n<p class=\"bwalignc\"><i>Signatera<\/i><sup><i>\u2122 <\/i><\/sup><i>Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera\u2019s ESMO program<\/i><\/p>\n<p class=\"bwalignl\">AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.natera.com&amp;esheet=54624263&amp;newsitemid=20261018851261&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=004d3a1635f37ae6bcbc34aadd01bb52\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23\u201326 in Madrid, Spain.<\/p>\n<p>New evidence highlights the power of Natera\u2019s latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrated an industry-leading analytical limit of detection (LOD95) below 1 part per million (ppm), and detection observed significantly below 1 part per 10 million.<sup>1<\/sup><\/p>\n<p>Spanning tumor types and treatment modalities, multiple ESMO presentations will show that serial ctDNA testing provides meaningful clinical benefit:<\/p>\n<ul class=\"bwlistdisc\">\n<li><i>ICONIC trial in gastroesophageal cancer (abstract 2901P):<\/i> Among patients treated with perioperative chemotherapy and immunotherapy, MRD clearance during neoadjuvant therapy was strongly associated with a lower risk of recurrence and a favorable pathologic response. Signatera Genome with Phased and Structural Variants detected all evaluable recurrences during surveillance, with a &gt;7.3 month median lead time over standard imaging.<\/li>\n<li><i>SAGITTARIUS trial in colon cancer (abstract 808P): <\/i>In this phase III trial, post-operative patients were randomized to a physician-choice adjuvant treatment plan prior to receiving MRD results to assess impact. The analysis showed that Signatera results influenced a change to providers\u2019 pre-planned treatment for one in three patients, of which 87% were treatment de-escalated based on MRD negativity.<\/li>\n<li><i>Colorectal\/Breast cancer (abstract 4258P): <\/i>In a retrospective analysis of surveillance monitoring of stage I-III breast and colorectal cancer survivors, serial Signatera negativity was associated with an extremely low 2-year recurrence risk, which may help refine risk stratification and inform eligibility for solid organ transplant earlier than current methodologies.<\/li>\n<li><i>Breast cancer (abstract 1770RO): <\/i>In HER2+ metastatic breast cancer, an analysis of exceptional responders on anti-HER2 therapy showed 81% with sustained MRD-negativity during serial monitoring, supporting the potential for Signatera-guided de-escalation.<\/li>\n<li><i>MDT-Bridge trial in non-small cell lung cancer (NSCLC) (abstract LBA62)<\/i>: This phase II trial evaluated MRD clearance from baseline to pre-surgery\/pre-CRT using the Clarity<sup>\u2122<\/sup> assay with <i>phased variant <\/i>technology.<\/li>\n<li><i>MRD-guided reflex to liquid CGP drives actionable treatment decisions (abstract 4260P)<\/i>: In a cohort of 50 patients across 10 tumor types, Signatera, complemented by reflex to blood-based comprehensive genomic profiling (liquid CGP), identified clinically relevant biomarkers in 18 patients, including <i>ESR1, BRAF, FGFR3, and BRCA2<\/i>.<\/li>\n<\/ul>\n<p>\u201cWe are pleased to share data at ESMO that highlights our expanding diagnostics portfolio, which includes the newest version of our ultrasensitive Signatera Genome test,\u201d said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection, Natera. \u201cThe incorporation of phased and structural variants results in the ability to detect ctDNA significantly below 1 part per 10 million and takes MRD sensitivity into a range we haven\u2019t seen before.\u201d<\/p>\n<p><strong>The 2026 ESMO program featuring Natera\u2019s technologies includes:<\/strong><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 4258P<\/b><br \/>Presenter: Hideaki Bando, M.D., Ph.D.<br \/>Poster:<i> Circulating tumor DNA (ctDNA)-informed risk prediction in breast (BC) and colorectal cancer (CRC) patients (pts): implications for solid organ transplant (SOT)<\/i><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 4265P<\/b><br \/>Presenter: Luca Lazzari, Ph.D.<br \/>Poster: <i>Genomic alterations and association with post-surgery circulating tumor DNA status in early-stage colon cancer<\/i><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 4764P<\/b><br \/>Presenter: Yousef Zakharia, M.D.<br \/>Poster: <i>Outcomes in patients with muscle-invasive bladder cancer with divergent differentiation or histologic subtypes from NIAGARA<\/i><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 3633P<\/b><br \/>Presenter: Nicholas Bingham, BS<br \/>Poster: <i>Utility of circulating tumor DNA in patients with renal cell carcinoma at increased risk of recurrence after resection<\/i><\/p>\n<p><b>October 23, 2026, 16:15 CET | Abstract 542RO<\/b><br \/>Presenter: Yukinori Ozaki, M.D., Ph.D.<br \/>Rapid Oral: <i>Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1<\/i><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 4462P<\/b><br \/>Presenter: Benjamin O. Herzberg, M.D.<br \/>Poster: <i>Genomic landscape of the SKI Complex in a large multi-cancer cohort of 260,000 tumors<\/i><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 4276P<\/b><br \/>Presenter: Nicholas Hornstein, M.D., Ph.D.<br \/>Poster: <i>Quantification of circulating tumor DNA (ctDNA) in patients using a multi-cancer, methylation-based assay for tissue-free treatment response monitoring (tf-TRM)<\/i><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 4260P<\/b><br \/>Presenter: Jason A. Mouabbi, M.D.<br \/>Poster: <i>Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors<\/i><\/p>\n<p><b>October 23, 2026, 15:15 CET | Abstract 4417P<\/b><br \/>Presenter: Fizza Mughal, Ph.D.<br \/>Poster: <i>Plasma whole-exome sequencing (pWES) reveals somatic landscape and clonal dynamics in metastatic urothelial carcinoma<\/i><\/p>\n<p><b>October 24, 2026, 10:15 CET | Abstract 4741RO<\/b><br \/>Presenter: Matthew D. Galsky, M.D.<br \/>Rapid Oral: <i>Exploratory analysis of molecular subtypes and association with treatment outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) from NIAGARA<\/i><\/p>\n<p><b>October 24, 2026, 12:00 CET | Abstract 574P<\/b><br \/>Presenter: Adrianne L. Rolfes, M.D.<br \/>Poster: <i>Neoadjuvant anti-PD1 without chemotherapy in early-stage luminal B breast cancer<\/i><\/p>\n<p><b>October 24, 2026, 12:00 CET | Abstract 583P<\/b><br \/>Presenter: Teck Long King<br \/>Poster: <i>\u22654<\/i><i>positive nodes identify a population enriched for ctDNA-guided adjuvant treatment escalation in ER+\/HER2- early breast cancer<\/i><\/p>\n<p><b>October 25, 2026, 12:00 CET | Abstract 808P<\/b><br \/>Presenter: Vicente Alonso-Orduna, M.D.<br \/>Poster: <i>ctDNA negativity influences adjuvant treatment decisions: a paired counterfactual analysis from the SAGITTARIUS trial<\/i><\/p>\n<p><b>October 25, 2026 | Abstract 870eP<\/b><br \/>Presenter: Carlo Federici, Ph.D.<br \/>e-Poster: <i>Cost-effectiveness of a dynamic ctDNA-guided adjuvant strategy in stage II-III colon cancer, A SAGITTARIUS model-based analysis<\/i><\/p>\n<p><b>October 25, 2026, 12:00 CET | Abstract 810P<\/b><br \/>Presenter: Stefano Tamberi, M.D., Ph.D.<br \/>Poster: <i>ctDNA-guided adjuvant trials may miss the molecular residual disease (MRD) window: evidence of early attrition during trial allocation<\/i><\/p>\n<p><b>October 25, 2026, 12:00 CET | Abstract 820P<\/b><br \/>Presenter: Benjamin Weinberg, M.D.<br \/>Poster: <i>Leronlimab (LRM) in combination with trifluridine\/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study<\/i><\/p>\n<p><b>October 25, 2026, 12:00 CET | Abstract 3542P<\/b><br \/>Presenter: Torben Van Zijp<br \/>Poster: <i>Organ preservation in rectal cancer after neoadjuvant radiotherapy, bevacizumab and atezolizumab: Translational analysis from the TARZAN study<\/i><\/p>\n<p><b>October 25, 2026, 12:00 CET | Abstract 2901P<\/b><br \/>Presenter: Marco Gerlinger, M.D., FRCP<br \/>Poster: <i>Clinical performance of the Signatera Genome assay in patients with localized gastroesophageal adenocarcinomas (GEA) treated with peri-operative FLOT and immunotherapy: ICONIC trial<\/i><\/p>\n<p><b>October 26, 2026, 10:15 CET | Abstract 1770RO<\/b><br \/>Presenter: Kazuki Nozawa, M.D.<br \/>Rapid Oral: <i>Ultra-sensitive MRD assessment in long-term complete responders to anti-HER2 therapy in HER2-positive metastatic breast cancer: Initial results from HER2-CR study<\/i><\/p>\n<p><b>October 26, 2026, 10:15 CET | Abstract LBA62<\/b><br \/>Presenter: Jonathan Spicer, M.D., Ph.D.<br \/>Rapid Oral: <i>ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable\/borderline resectable stage IIB\u2013IIIB NSCLC from MDT-BRIDGE<\/i><\/p>\n<p><strong>References<\/strong><\/p>\n<ol class=\"bwlistdecimal\">\n<li>William B, Galanina N, Iqbal M, et al. ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma. SOHO 2026 Annual Meeting, Houston, TX, September 9-12, 2026.<\/li>\n<\/ol>\n<p><strong>About Natera<\/strong><\/p>\n<p>Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54624263&amp;newsitemid=20261018851261&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=2&amp;md5=bcc76507214941f133cd0a98efad422e\">www.natera.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in &#8220;Risk Factors&#8221; in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.natera.com%2Fnews%2Fdefault.aspx&amp;esheet=54624263&amp;newsitemid=20261018851261&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=3&amp;md5=f545185d63d54029861aaca1dc6450f1\">www.natera.com\/investors<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54624263&amp;newsitemid=20261018851261&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=b855970c9672a238edb7647db86ba18e\">www.sec.gov<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261018851261\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261018851261\/en\/<\/a><\/span><\/p>\n<p class=\"bwalignl\">Investor Relations: Mike Brophy, CFO, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:investor@natera.com\">investor@natera.com<\/a><br \/>Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:pr@natera.com\">pr@natera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas Europe Spain United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Surgery Genetics Clinical Trials Biotechnology Health Pharmaceutical Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261018851261\/en\/1736351\/3\/Natera_floret_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations Signatera\u2122 Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera\u2019s ESMO program AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23\u201326 in Madrid, Spain. New evidence highlights the power of Natera\u2019s latest ultrasensitive molecular residual disease (MRD) technology, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011125","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations Signatera\u2122 Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera\u2019s ESMO program AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23\u201326 in Madrid, Spain. New evidence highlights the power of Natera\u2019s latest ultrasensitive molecular residual disease (MRD) technology, &hellip; Continue reading &quot;ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-18T22:13:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology\",\"datePublished\":\"2026-10-18T22:13:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/\"},\"wordCount\":1481,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/\",\"name\":\"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-18T22:13:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/","og_locale":"en_US","og_type":"article","og_title":"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology - Market Newsdesk","og_description":"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations Signatera\u2122 Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera\u2019s ESMO program AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23\u201326 in Madrid, Spain. New evidence highlights the power of Natera\u2019s latest ultrasensitive molecular residual disease (MRD) technology, &hellip; Continue reading \"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-18T22:13:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology","datePublished":"2026-10-18T22:13:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/"},"wordCount":1481,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/","name":"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-18T22:13:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261018851261r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-2026-presentations-deepen-the-evidence-base-for-nateras-oncology-portfolio-and-leadership-in-ultrasensitive-mrd-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ESMO 2026 Presentations Deepen the Evidence Base for Natera\u2019s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011125"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011125\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}